Massalha Eias, Brodov Yafim, Oren Daniel, Fardman Alex, Natanzon Sharon Shalom, Mazin Israel, Beinart Roy, Goldkorn Ronen, Konen Eli, Segni Elio Di, Segev Amit, Beigel Roy, Matetzky Shlomi, Goitein Orly
The Olga and Lev Leviev Heart Center, Sheba Medical Center, Affiliated With the Sackler School of Medicine, Tel Aviv University, Ramat Gan, Israel.
Diagnostic Imaging, Sheba Medical Center, Affiliated With the Sackler School of Medicine, Tel Aviv University, Ramat Gan, Israel.
Front Cardiovasc Med. 2022 Feb 24;9:752626. doi: 10.3389/fcvm.2022.752626. eCollection 2022.
Post myocardial infarction pericarditis is considered relatively rare in the current reperfusion era. The true incidence of pericardial involvement may be underestimated since the diagnosis is usually based on clinical and echocardiographic parameters.
This study aims to document the incidence, extent, and prognostic implication of pericardial involvement in ST-segment elevation myocardial infarction (PISTEMI) using cardiac MRI (CMR).
One hundred and eighty-seven consecutive ST-segment elevation myocardial infarction patients underwent CMR on day 5 ± 1 following admission, including steady-state free precession (SSFP) and late Gadolinium enhancement (LGE) sequences. Late Gadolinium enhancement and microvascular obstruction (MVO) were quantified as a percentage of left ventricular (LV) mass. Late Gadolinium enhancement was graded for transmurality according to the 17 AHA left ventricle (LV) segment model (LGE score). Late pericardial enhancement (LPE), the CMR evidence of pericardial involvement, was defined as enhanced pericardium in the LGE series and was retrospectively recorded as present or absent according to the 17 AHA segments. Late pericardial enhancement was evaluated adjacent to the LV, the right ventricle, and both atria. Clinical, laboratory, angiographic, and echocardiographic data were collected. Clinical follow-up for major adverse cardiac events (MACE) was documented and correlated with CMR indices, including LGE, MVO, and LPE.
Late pericardial enhancement (LPE+) was documented in 77.5% of the study cohort. A strong association was found between LPE and the degree and extent of myocardial injury (LGE, MVO). Both LGE and MVO were significantly correlated with increased MACE on follow-up. On the contrary, LPE presence, either adjacent to the LV or the other cardiac chambers, was associated with a lower MACE rate in a median of 3 years of follow-up HR 0.39, 95% CI (0.21-0.7), = 0.002, and HR 0.48, 95% CI (0.26-0.9), = 0.02, respectively.
Prognostic implication of pericardial involvement in ST-segment elevation myocardial infarction was documented by CMR in 77.5% of our STEMI cohort. Late pericardial enhancement presence correlated significantly with the extent and severity of the myocardial damage. Unexpectedly, it was associated with a considerably lower MACE rate in the follow-up period.
在当前的再灌注时代,心肌梗死后心包炎被认为相对少见。由于心包受累的诊断通常基于临床和超声心动图参数,其实际发生率可能被低估。
本研究旨在利用心脏磁共振成像(CMR)记录ST段抬高型心肌梗死(PISTEMI)中心包受累的发生率、范围及预后意义。
187例连续的ST段抬高型心肌梗死患者在入院后第5±1天接受CMR检查,检查序列包括稳态自由进动(SSFP)和钆延迟增强(LGE)序列。钆延迟增强和微血管阻塞(MVO)以左心室(LV)质量的百分比进行量化。根据17节段美国心脏协会(AHA)左心室(LV)节段模型对钆延迟增强的透壁程度进行分级(LGE评分)。晚期心包增强(LPE),即心包受累的CMR证据,定义为LGE序列中的心包强化,并根据17节段AHA节段进行回顾性记录,记录其有无。在左心室、右心室和双心房附近评估晚期心包增强情况。收集临床、实验室、血管造影和超声心动图数据。记录主要不良心脏事件(MACE)的临床随访情况,并与CMR指标(包括LGE、MVO和LPE)进行关联分析。
研究队列中77.5%的患者记录到晚期心包增强(LPE+)。发现LPE与心肌损伤的程度和范围(LGE、MVO)之间存在密切关联。LGE和MVO均与随访期间MACE的增加显著相关。相反,在中位3年的随访中,无论LPE出现在左心室还是其他心腔附近,其MACE发生率均较低,风险比(HR)分别为0.39,95%可信区间(CI)(0.21 - 0.7),P = 0.002,以及HR 0.48,95%CI(0.26 - 0.9),P = 0.02。
在我们的STEMI队列中,77.5%的患者通过CMR记录到ST段抬高型心肌梗死心包受累的预后意义。晚期心包增强的出现与心肌损伤的范围和严重程度显著相关。出乎意料的是,在随访期间它与显著更低的MACE发生率相关。